US Stock MarketDetailed Quotes
BPTH Bio-Path Holdings
- 1.750
- -0.060-3.31%
Close Jul 22 16:00 ET
3.64MMarket Cap-69P/E (TTM)
1.800High1.720Low41.85KVolume1.760Open1.810Pre Close73.79KTurnover2.01%Turnover RatioLossP/E (Static)2.08MShares22.00052wk High-1.39P/B3.64MFloat Cap1.59152wk Low--Dividend TTM2.08MShs Float23999.988Historical High--Div YieldTTM4.42%Amplitude1.591Historical Low1.763Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Bio-Path Holdings Stock Forum
Bio Path Holdings : Prexigebersen Phase 2 Clinical Trial Currently Paused for Interim Analysis, Amendment Preparation, FDA Review
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Bio-Path Holdings (NASDAQ:BPTH), a biotechnology firm, has provided an update on its clinical programs and expansion plans. The company has made significant progress across multiple cancer studies and has completed the development of oncology molecular biomarkers. Additionally, Bio-Path is preparing preclinical studies for prexigebersen as a potential obesity treatment. The company's clinical developm...
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combinati...
No comment yet